Related Experiment Video
Updated: Aug 7, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Type I interferon signaling induces a delayed antiproliferative response in Calu-3 cells during SARS-CoV-2 infection
Juliana Bragazzi Cunha1, Kyle Leix1, Emily J Sherman1
1Department of Internal Medicine, University of Michigan Medical School, Ann Arbor MI.
Abstract:
Disease progression during SARS-CoV-2 infection is tightly linked to the fate of lung epithelial cells, with severe cases of COVID-19 characterized by direct injury of the alveolar epithelium and an impairment in its regeneration from progenitor cells. The molecular pathways that govern respiratory epithelial cell death and proliferation during SARS-CoV-2 infection, however, remain poorly understood. We now report a high-throughput CRISPR screen for host genetic modifiers of the survival and proliferation of SARS-CoV-2-infected Calu-3 respiratory epithelial cells. The top 4 genes identified in our screen encode components of the same type I interferon signaling complex - IFNAR1, IFNAR2, JAK1, and TYK2. The 5th gene, ACE2, was an expected control encoding the SARS-CoV-2 viral receptor. Surprisingly, despite the antiviral properties of IFN-I signaling, its disruption in our screen was associated with an increase in Calu-3 cell fitness. We validated this effect and found that IFN-I signaling did not sensitize SARS-CoV-2-infected cultures to cell death but rather inhibited the proliferation of surviving cells after the early peak of viral replication and cytopathic effect. We also found that IFN-I signaling alone, in the absence of viral infection, was sufficient to induce this delayed antiproliferative response. Together, these findings highlight a cell autonomous antiproliferative response by respiratory epithelial cells to persistent IFN-I signaling during SARS-CoV-2 infection. This response may contribute to the deficient alveolar regeneration that has been associated with COVID-19 lung injury and represents a promising area for host-targeted therapeutic development.
Insights
Type I interferon signaling impairs lung cell proliferation after SARS-CoV-2 infection, hindering regeneration. This finding offers new therapeutic targets for COVID-19 lung injury.
Area of Science:
- Virology
- Cell Biology
- Immunology
Background:
- COVID-19 severity correlates with lung epithelial cell damage and impaired regeneration.
- Molecular mechanisms controlling lung cell death and proliferation during SARS-CoV-2 infection are not fully understood.
Approach:
- A high-throughput CRISPR screen identified host genetic factors influencing SARS-CoV-2-infected lung epithelial cell survival and proliferation.
- Key genes identified included components of the type I interferon (IFN-I) signaling pathway (IFNAR1, IFNAR2, JAK1, TYK2).
Key Points:
- Disrupting IFN-I signaling unexpectedly increased infected cell fitness.
- IFN-I signaling inhibited, rather than sensitized to death, the proliferation of surviving cells post-viral replication.
- This antiproliferative effect was observed even without viral infection, indicating a cell-autonomous response.
Conclusions:
- Persistent IFN-I signaling triggers a cell-autonomous antiproliferative response in respiratory epithelial cells during SARS-CoV-2 infection.
- This response may impede alveolar regeneration in COVID-19 lung injury.
- Targeting this IFN-I-mediated pathway presents a potential therapeutic strategy for host-directed COVID-19 treatments.

